Alkermes News and Activities

Presence

Alkermes develops and makes medicines for mental health, addiction, and serious neurological conditions. It provides drug development and manufacturing services for patients, healthcare providers, and pharmaceutical partners.

Alkermes products and services overview:

Mental health medicines
Addiction treatments
Neurology therapies
Drug development
Manufacturing services

Revenue: ~$2 billion

Employees: 2,000

Headquarters: Dublin, Ireland

Alkermes is one of the...

Alkermes is a company listed under the stock ticker ALKS (US).

Alkermes has a direct presence in 2 countries.

They are in:

Biotechnology50%
Pharmaceuticals50%

Acquisition, funding and merger involving Alkermes.

Alkermes has announced the acquisition of Avadel Pharmaceuticals (posted on November 19 2025).

Executives

View the org chart displaying its 40 main executives

Most searched biographies at Alkermes

Popular executive movements at Alkermes

Tom Skoff, who was Vice President Information Technology, is promoted to Senior Vice President, Chief Information Officer (posted on April 15 2026).
Jenna Herby has joined the company as Senior Clinical Trial Manager (posted on April 15 2026).
Thomas Harvey, Chief Information Officer and Senior Vice President, Information Technology, has left the company (posted on April 15 2026).

Click here to view some more movements at Alkermes

Create your alert
to follow the executive moves at Alkermes.

Biotechnology

Alkermes has 2,415 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).
Boundless Bio will change its company name to Serapha Bio on Dec 31, 2026. (posted on June 23 2026).